【摘要】 细胞色素Ｐ４５０ ２Ｃ１９（ＣＹＰ２Ｃ１９）又称为Ｓ－美芬妥英羟化酶，它的两个突变型等位基因ＣＹＰ２Ｃ１９ｍｌ和ＣＹＰ２Ｃ１９ｍ２是引起ＣＹＰ２Ｃ１９酶活性缺陷的原因．运用等位基因特异扩增法（ＡＳＡ）对肺癌患者、膀胱癌患者及正常人进行了ＣＹＰ２Ｃ１９基因分型研究，以探索ＣＹＰ２Ｃ１９酶活性与肺癌、膀胱癌易患性的关系．经过对７４例肺癌患者、５０例膀胱癌患者和７０例对照组的测定，发现肺癌组慢代谢的发生率为３２．４％，膀胱癌患者的慢代谢发生率为４．０％，而对照组中该值为 １５．７％，经ｘ~２统计有显著性差异；实验表明，ＣＹＰ２Ｃ１９酶活性的降低增加了肺癌发生的可能性，却降低了患膀胱癌的危险性．结果显示，ＣＹＰ２Ｃ１９参与了肺癌致癌物的清除和膀胱癌致癌物的激活，提示ＣＹＰ２Ｃ１９是一种肿瘤相关基因．更多还原

【Abstract】 Cytochrome P450 2C19(CYP2C19, S-mephenytoin hydroxylase) enzyme deficiency was caused by two mutant alleles: CYP2C19ml and CYP2C19m2. An allele-specific amplification based CYP2C19 genotyping method was employed to analyze 74 cases of lung cancer patients, 50 cases of bladder cancer patients and a control group with 70 healthy subjects. It was found that the frequency of poor metabolizers of CYP2C19 was 32.4% in lung cancer group, 4.0% in bladder cancer group and 15.7% in control group. There were extremely statistic differences between control group and experimental groups. Poor metabolisers of CYP2C19 had an increased risk of lung cancer, but had a decreased risk of bladder cancer. It suggested that CYP2C19 is a new tumor-related gene and the enzyme may participate in the inactivation of carcinogens of lung cancer and the activation of procarcinogens of bladder cancer.更多还原